Spravato transportation: rides home after the 2-hour watch, and booking a twice-weekly course

How many rides does a Spravato course take?

The first eight weeks of treatment-resistant depression care take 12 visits, which is 12 round trips. The FDA label sets twice a week for weeks 1 to 4, which it calls the induction phase, then once a week for weeks 5 to 8. From week 9 the dose is given every two weeks or weekly, and the label tells prescribers to use the least frequent schedule that keeps the patient in remission or response. These are outpatient behavioral health rides, so the general rules in the behavioral health transportation guide apply to them as well.

The label also sets a review point at week 4. The prescriber evaluates benefit at the end of the induction phase to decide whether treatment continues, so a ride series booked for months may end or change after week 4. The separate indication, depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, is labeled for twice a week for four weeks, with benefit evaluated after those four weeks.

A missed session does not reset the course. If depression has not worsened, the patient stays on the current schedule. If it has worsened during maintenance, the label says the prescriber may consider returning to the previous schedule, for example from weekly back to twice weekly. A rider who misses a visit can therefore end up needing more rides, not fewer, so ask the clinic to tell you whenever the schedule changes. The standing orders guide covers how a broker renews or changes a recurring series.

How long is a Spravato visit, and when should the ride home be booked?

A visit lasts longer than two hours, and the end time is a clinical decision, so book the ride home to start when the clinic says the patient is ready. The boxed warning requires monitoring for sedation, dissociation and respiratory depression for at least 2 hours at each treatment session, “followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.”

The visit has more parts than the watch itself:

1. Before the dose. The clinic checks blood pressure first. The label advises patients not to eat for at least 2 hours before the dose or drink liquids for at least 30 minutes before it, because nausea and vomiting can follow.
2. The dose. A 56 mg dose is two nasal spray devices and an 84 mg dose is three, with a 5-minute rest between devices.
3. The watch. The clinic reassesses blood pressure at about 40 minutes and keeps monitoring, including pulse oximetry, for at least two hours. The FDA’s patient monitoring form records the total time from the first device to the end of monitoring and asks the clinic to give a reason if a patient was watched for less than two hours.
4. The release. A patient whose blood pressure is falling and who has looked clinically stable for at least two hours may be discharged at the end of the monitoring period. If not, monitoring continues.

A pickup set for two hours after arrival will be early, because the two hours start after the dose. The better booking is a will-call return that the clinic’s front desk or the rider triggers when the patient is cleared. The will-call guide covers how dispatch holds a van for a return like this. There is no at-home dose to replace the ride. The REMS requires each dose to be taken under direct supervision in a certified setting, and its program overview says the medicine must never be dispensed directly to a patient for home use.

Who may take a Spravato patient home?

The current FDA documents require that the patient have a ride home but do not say who must provide it, so ask the clinic about its own rule before the first dose. The label says patients “will need to arrange transportation home following treatment.” The REMS Program Overview lists the same duty for the patient: make arrangements to safely get home after receiving Spravato.

The Medication Guide changed on this point in September 2026. The patient information in the April 2025 label told patients to “plan for a caregiver or family member to drive you home after taking SPRAVATO.” The Medication Guide approved September 17, 2026 says “You will need someone to drive you home after each treatment with SPRAVATO.” The FDA’s approval letter describes the update as one that improves readability and clarifies the transportation requirements following treatment. None of the FDA documents mentions a taxi, a rideshare or a ride company, whether to allow or to bar one.

That leaves three practical cases for a ride company:

• The clinic accepts a professional driver alone. Book a standard round trip with a will-call return. Confirm with the clinic that the driver may collect the patient at the front desk, since it may want to hand the patient to a named person.
• The clinic wants a person with the patient. Book the escort a seat on both legs, as an escort or attendant. The escort rides, and the driver drives. The general responsible adult rule is explained in the guide to rides home after outpatient surgery.
• The clinic has not decided. Hold the series until it answers. A rider the clinic will not release to a driver has waited two hours for nothing.

The label’s driving rule is separate from the ride home. Before each dose, the label tells clinics to instruct patients not to drive a motor vehicle or operate machinery until the next day following a restful sleep. A patient on a twice-weekly schedule is not driving on either treatment day, which is why the ride is not a one-time need.

What can a driver notice after a dose?

A driver may carry someone who is quiet, unsteady or briefly unwell, and the label explains why. In the clinical trials, 48% to 61% of treated patients showed sedation on an observer’s alertness scale, and 0.3% to 0.4% lost consciousness. Dissociation, meaning distortions of time and space, illusions, and a feeling of being detached from one’s surroundings or oneself, was measured in 61% to 84% of treated patients. The label calls it transient and says it occurred on the day of dosing. Nausea and vomiting mostly resolved the same day, with a median duration not exceeding 1 hour in most patients. By two hours after the dose, cognitive test performance matched placebo in the healthy volunteer study, and sleepiness matched placebo by four hours.

A driver is not a clinician and the rider has already been released by one. The ride is still a place for a few plain habits:

• Seat the rider where the driver can see them, and keep the ride smooth. A rider who is tired may not ask for help.
• Keep a bag and tissues within reach. Nausea is a listed effect.
• Give instructions to the escort as well as the rider when one is aboard. A rider who feels disconnected may not retain them.
• Call 911 for the signs the label sends to emergency care. For blood pressure problems the label lists chest pain and shortness of breath, and sudden severe headache, visual disturbances, seizures or diminished consciousness. A rider who cannot be woken or has trouble breathing is also a 911 call. The steps are in the guide to medical emergencies on board.

The label also tells caregivers to watch for new suicidal thoughts, especially early in treatment and when the dose changes. A driver who hears a rider talk about self-harm follows the company’s crisis policy and calls 911 when the danger is immediate. The behavioral health transportation guide and the guide to mental health first aid for drivers cover what to say and when to escalate. Keep the destination private too, since a clinic address tells anyone who reads the manifest what the trip is for.

Does Medicaid pay for rides to Spravato?

Medicaid pays for a ride to Spravato only when Spravato treatment is a covered service for that member and the member has no other way to get there. CMS describes the transportation assurance in SMD 23-006 as covering rides needed to reach a covered service for beneficiaries with no other means of transportation. It is not a duty to pay for every trip. The same guide counts a transportation attendant among the related travel expenses a state must cover when the attendant is necessary, with the attendant’s salary included if the attendant is not a family member.

Coverage of the treatment itself belongs to the member’s plan and state program, so the clinic or the plan is the place to confirm it. Once the visits are covered, the ride goes through the member’s broker or plan the same way as dialysis or physical therapy: a standing order for the series, a return that waits on the clinic, and an escort request where the clinic requires one. If the visits are not covered, the ride is private pay. The private pay guide covers pricing it.

What about IV ketamine clinics?

Clinics that give ketamine by infusion for depression are using a drug whose FDA label covers anesthesia, not depression, so ask each clinic about its own ride rule and its billing. The Ketalar label, revised in March 2026, lists use as a general anesthetic and tells patients not to drive an automobile, operate hazardous machinery or do hazardous activities within 24 hours of receiving it. A clinic’s own instructions govern what it expects for the ride home, and whether a payer covers the visit is for the clinic and the member’s plan to say. When a payer does not cover a visit, the ride is a private-pay trip and is priced like any other round trip with a flexible return.

Keeping a Spravato series on the board in HealthRide

HealthRide lets you set the twice-weekly visits up once, and the trips keep appearing on the board without being entered one by one. The return from the clinic can wait as a flexible trip that goes live when the clinic calls the patient ready. If the clinic wants a person with the patient, add them as an escort on the trip, and the family can watch the van’s progress from a text link. See recurring trips for how series work.